Myogen shares soar on mid-stage trial results

Shares of Myogen zoomed up 60 percent after the biotech reported that a Phase IIb trial for the hypertension drug darusentan demonstrated a statistically significant result among patients resistant to standard treatments. About 50 million Americans and 1 billion people worldwide suffer from hypertension, and some 20 percent to 30 percent are unable to reach recommended blood pressure levels with currently approved pharmaceuticals.

"As an endothelin receptor antagonist, darusentan affects blood pressure through a mechanism of action different than those of currently approved antihypertensive drugs," said J. William Freytag, president and CEO of Myogen. "The results of this trial indicate darusentan could provide additional blood pressure lowering benefit in this patient population."

- read this press release for more information

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.